JP2019515683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515683A5 JP2019515683A5 JP2019503642A JP2019503642A JP2019515683A5 JP 2019515683 A5 JP2019515683 A5 JP 2019515683A5 JP 2019503642 A JP2019503642 A JP 2019503642A JP 2019503642 A JP2019503642 A JP 2019503642A JP 2019515683 A5 JP2019515683 A5 JP 2019515683A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence defined
- sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 9
- 230000008685 targeting Effects 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 102100030477 Plectin Human genes 0.000 claims 5
- 108010054050 Plectin Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000002105 nanoparticle Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 239000006096 absorbing agent Substances 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 239000007850 fluorescent dye Substances 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 239000000891 luminescent agent Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022193511A JP2023036612A (ja) | 2016-04-08 | 2022-12-02 | プレクチン１結合性抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662320117P | 2016-04-08 | 2016-04-08 | |
| US62/320,117 | 2016-04-08 | ||
| PCT/US2017/026711 WO2017177199A2 (en) | 2016-04-08 | 2017-04-07 | Plectin-1 binding antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022193511A Division JP2023036612A (ja) | 2016-04-08 | 2022-12-02 | プレクチン１結合性抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515683A JP2019515683A (ja) | 2019-06-13 |
| JP2019515683A5 true JP2019515683A5 (OSRAM) | 2020-05-21 |
| JP7197078B2 JP7197078B2 (ja) | 2022-12-27 |
Family
ID=60001509
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503642A Active JP7197078B2 (ja) | 2016-04-08 | 2017-04-07 | プレクチン１結合性抗体およびその使用 |
| JP2022193511A Pending JP2023036612A (ja) | 2016-04-08 | 2022-12-02 | プレクチン１結合性抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022193511A Pending JP2023036612A (ja) | 2016-04-08 | 2022-12-02 | プレクチン１結合性抗体およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11168145B2 (OSRAM) |
| EP (1) | EP3439692A4 (OSRAM) |
| JP (2) | JP7197078B2 (OSRAM) |
| KR (2) | KR102611444B1 (OSRAM) |
| CN (2) | CN109414489B (OSRAM) |
| WO (1) | WO2017177199A2 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7197078B2 (ja) | 2016-04-08 | 2022-12-27 | ジィールバイオ，インコーポレーテッド | プレクチン１結合性抗体およびその使用 |
| CN112105380A (zh) * | 2017-10-11 | 2020-12-18 | 埃缇健康公司D/B/A泽尔拜尔 | 网蛋白-1结合抗体和其用途 |
| US11890352B2 (en) | 2018-02-27 | 2024-02-06 | University Of Virginia Patent Foundation | Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer |
| EP4423125A1 (en) * | 2021-10-29 | 2024-09-04 | Zielbio, Inc. | Cancer specific plectin-1 specific antibodies and methods of use thereof |
| CN115947855B (zh) * | 2022-05-20 | 2023-10-27 | 杭州邦顺制药有限公司 | 抗cd24抗体的制备及其用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| CN1297902A (zh) * | 1999-11-24 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人网蛋白80和编码这种多肽的多核苷酸 |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20040101874A1 (en) | 2002-04-12 | 2004-05-27 | Mitokor Inc. | Targets for therapeutic intervention identified in the mitochondrial proteome |
| WO2004108948A2 (en) * | 2003-06-04 | 2004-12-16 | President And Fellows Of Harvard College | Systems, methods and kits for characterizing phosphoproteomes |
| US7842466B1 (en) * | 2005-09-16 | 2010-11-30 | Celera Corporation | Colon disease targets and uses thereof |
| KR20100074177A (ko) | 2007-09-10 | 2010-07-01 | 유니버시티 오브 매사추세츠 | 미토콘드리아-표적화된 항-종양 물질 |
| JP2011506614A (ja) | 2007-12-17 | 2011-03-03 | ダイアックス コーポレーション | Ｍｍｐ−１４結合タンパク質を含む、骨溶解性障害を処置するための組成物および方法 |
| WO2009129220A2 (en) * | 2008-04-14 | 2009-10-22 | The Gereral Hospital Corporation | Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
| JP2013510094A (ja) * | 2009-11-05 | 2013-03-21 | ユニバーシティ オブ バージニア パテント ファウンデーション | がんのバイオマーカーとしてプレクチン−１を検出するための組成物および方法 |
| CN104717980A (zh) * | 2012-08-14 | 2015-06-17 | 米纳瓦生物技术公司 | 干细胞增强疗法 |
| US9856315B2 (en) * | 2014-10-15 | 2018-01-02 | Cell Signaling Technology, Inc. | Methylation and acetylation sites |
| US10611796B2 (en) | 2016-03-16 | 2020-04-07 | Council Of Scientific & Industrial Research | Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines |
| JP7197078B2 (ja) | 2016-04-08 | 2022-12-27 | ジィールバイオ，インコーポレーテッド | プレクチン１結合性抗体およびその使用 |
| CN112105380A (zh) | 2017-10-11 | 2020-12-18 | 埃缇健康公司D/B/A泽尔拜尔 | 网蛋白-1结合抗体和其用途 |
-
2017
- 2017-04-07 JP JP2019503642A patent/JP7197078B2/ja active Active
- 2017-04-07 CN CN201780035683.6A patent/CN109414489B/zh active Active
- 2017-04-07 EP EP17779953.3A patent/EP3439692A4/en active Pending
- 2017-04-07 KR KR1020237000451A patent/KR102611444B1/ko active Active
- 2017-04-07 CN CN202210906247.4A patent/CN116333140A/zh active Pending
- 2017-04-07 KR KR1020187032404A patent/KR102486507B1/ko active Active
- 2017-04-07 WO PCT/US2017/026711 patent/WO2017177199A2/en not_active Ceased
- 2017-04-07 US US16/091,928 patent/US11168145B2/en not_active Expired - Fee Related
-
2021
- 2021-11-03 US US17/517,934 patent/US20220119546A1/en not_active Abandoned
-
2022
- 2022-12-02 JP JP2022193511A patent/JP2023036612A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191609T1 (hr) | Protein | |
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| JP2019515683A5 (OSRAM) | ||
| JP2010535713A5 (OSRAM) | ||
| Maleki et al. | Future prospects of monoclonal antibodies as magic bullets in immunotherapy | |
| JP2019535670A5 (OSRAM) | ||
| JP2017519759A5 (OSRAM) | ||
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| HRP20180507T1 (hr) | Identifikacija antigena povezanih s tumorom za dijagnozu i terapiju | |
| HRP20151136T1 (hr) | Monoklonska antitijela protiv klaudina-18 za lijeäśenje kancera | |
| HRP20140341T1 (hr) | Antitijela na angiopoetin-1 i angiopoetin-2 i njihova uporaba | |
| JP2018506961A5 (OSRAM) | ||
| JP2013506428A5 (OSRAM) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2020501598A5 (OSRAM) | ||
| JP2015163068A5 (OSRAM) | ||
| HRP20140899T1 (hr) | Anti-cxcr4 antitijela i njihova upotreba za lijeäśenje karcinoma | |
| JP2014522850A5 (OSRAM) | ||
| HRP20110599T1 (hr) | Antitijela protiv toksina clostridium difficile i njihove primjene | |
| JP2017149720A5 (OSRAM) | ||
| JP2013517487A5 (OSRAM) | ||
| JP2017500057A5 (OSRAM) | ||
| JP2020514277A5 (OSRAM) | ||
| JP2017521054A5 (OSRAM) | ||
| JP2020534012A5 (OSRAM) |